A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Patients who are adherent to their endocrine therapy for at least 5 days in the week averaged over the 12-week period will be considered to have high level adherence, and those that took their ET for <5 days/ week would be considered non-adherent. PROMIS medication adherence questions will be used. In addition, the investigators will be observing pharmacy dispensing history and weekly adherence data reported by patients on the app. The proportion who are adherent will be summarized descriptively using frequencies and percentages, and confidence intervals will be reported using the Clopper-Pearson method.

Patient satisfaction will be measured by utilizing Consumer Assessment of Healthcare Providers and Systems Cancer Care Survey scores. Surveys will be conducted among all participants at baseline and at 12 weeks, regardless of their use of the app, to better understand any barriers to using the app and which aspects of the app were most useful to patients.Satisfaction outcomes will be summarized using descriptive measures. The survey measures the following: In the last 6 months, how many times did you visit this cancer center to get care from your drug therapy team? Do not include telephone calls or emails, where 0=None, 1=1 to 5 times, 2=6 to 10 times, 3=11 or more times.In the last 6 months, did you contact this cancer center to get an appointment for an illness, injury, or condition that needed care right away? where1=yes and 2=no.